Explain this page
Arphra AIPlain-English read on BridgeBio Pharma, Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $105.21 (+55.61%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.42% | +1.67% | -0.70% | +3.44% | -8.19% | -11.61% | +75.06% | +321.51% | +9.14% | +145.41% | +145.41% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$66.50
346 sh
Bid
$64.00
30 sh
Ask
$67.94
15 sh
Spread
$3.940
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $154.18M | -$197.24M | $-1.00 |
| Q3 Sep 2025 | $120.7M | -$182.74M | $-0.96 |
| Q2 Jun 2025 | $110.57M | -$181.9M | $-0.95 |
| Q1 Mar 2025 | $116.63M | -$167.42M | $-0.88 |
| Q4 Dec 2024 | $5.88M | -$265.05M | $-1.40 |
| Q3 Sep 2024 | $2.73M | -$162.04M | $-0.86 |
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launchesmarketbeat.com·May 13, 2026
- BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·May 13, 2026
- BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1globenewswire.com·May 12, 2026
- BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1globenewswire.com·May 12, 2026
- BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1globenewswire.com·May 12, 2026
- Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failureglobenewswire.com·May 11, 2026
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com·May 08, 2026
- BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updatesglobenewswire.com·May 07, 2026
Peers
No peer list available for BBIO.
Total assets
$936.03M
Total debt
$2.73B
Cash & equiv
$570.12M
Operating CF
-$445.91M
Free cash flow
-$447.01M
Buybacks
-$48.28M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $502.08M | -$569.09M | -$729.31M | $-3.79 | -145.26% |
| FY 2024 | $221.9M | -$592.97M | -$535.76M | $-2.88 | -241.44% |
| FY 2023 | $9.3M | -$607.37M | -$643.2M | $-3.95 | -6913.92% |
| FY 2022 | $77.65M | -$512.2M | -$481.18M | $-3.35 | -619.70% |
| FY 2021 | $69.72M | -$576.63M | -$562.54M | $-3.90 | -806.90% |